Jasper Therapeutics announced on December 2, 2025 that it had finished an internal review of the anomalous results from the July 2025 BEACON study and that it was presenting encouraging early data from the Phase 1b/2a ETESIAN study in adults with allergic asthma.
The BEACON investigation found that the unexpected lack of efficacy was attributable to patient‑selection errors rather than a defect in the briquilimab product. By confirming that the drug itself is safe and effective, the company has removed a major regulatory and clinical risk that could have delayed the planned Phase 2b study in chronic spontaneous urticaria slated for mid‑2026.
In the ETESIAN study, a single 180 mg subcutaneous dose of briquilimab produced significant reductions in sputum eosinophils at both six and twelve weeks, improved early and late asthmatic responses, and lowered serum tryptase levels, all while maintaining a favorable safety profile. These results suggest that mast‑cell depletion can translate beyond chronic urticaria into a high‑need, high‑cost disease area such as asthma.
CEO Ronald Martell said, “The investigation’s findings give us confidence that we can refine patient selection in future studies and that there are no product‑related issues.” He added that the data reinforce the company’s strategy of targeting mast‑cell‑driven diseases.
Jasper’s cash position stood at $50.9 million as of September 30, 2025, and a recent $30 million stock offering is expected to extend its runway into the first half of 2026. The asthma market is projected to grow from $18 billion in 2019 to $32.81 billion by 2032, while the chronic urticaria market is expected to rise from $2.45 billion in 2022 to $7.5 billion by 2029. The combination of a de‑risked product, a new indication, and a solid financial foundation positions Jasper to capture a meaningful share of these expanding markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.